Sikandar Lodi was the ruler of Delhi when Mir Syed Mohammad al Hussain al Hussaini al Termezi Haji al Haramain came to India and settled at Syed Nagli. He was a Baquari Syed who drew his lineage from Muhammad al Baqir. Perhaps the most important figure in the history of the Sayyid in Uttar Pradesh was Sayyid Basrullah Shustari, who moved from Mashad in Iran in 1549 and joined the court of the Mughal Emperor Akbar. Akbar appointed Shustari as his chief justice, who used his position to strengthen the status of the various Sayyid families. They were preferred in administrative posts and formed a privileged elite. When the Mughal Empire disintegrated, the Sayyid played an important role in the turbulent politics of the time. The new British colonial authorities that replaced the Mughals after the Battle of Buxar made a pragmatic decision to work with the various Sayyid jagirdars. Several Sayyid taluqdars in Awadh were substantial landowners under the British colonial regime, and many other Sayyid contributed to state administration. After the abolition of the zamindari system, many Sayyid zamindars (e.g. that of Ghazipur) had to leave their homes. Uttar Pradesh
The ancestor of the Bārha Sayyids, Sayyid Abul Farah Al Hussaini Al Wasti, left his original home in Wasit, Iraq, with his twelve sons at the end of the 13th century and migrated to India, where he obtained four villages in Sirhind-Fategarh.
Similar efficacy results were reported during 12-month follow-up: mean IOP decrease from baseline was 4.4-7.6 mmHg with brimonidine/timolol combination, compared to 2.7-5.5 mmHg with brimonidine and 3.9-6.2 mmHg with timolol. The incidence of treatment-related adverse events with the brimonidine/timolol combination was lower than that with brimonidine monotherapy but higher than that with timolol monotherapy.A 12-week prospective, randomized, double-blinded study in 371 glaucoma and ocular hypertension patients with inadequate IOP control on monotherapy compared the efficacy and safety of 0.2% brimonidine tartrate/0.5% timolol fixed combination twice daily with the concomitant use of 0.2% brimonidine tartrate twice daily and timolol 0.5% twice daily. The IOP-lowering effect of the fixed combination group was shown to be non-inferior to that of concomitant therapy. Incidence of adverse events was similar between groups. Society and culture
Commercial aspects
Allergan is the New Drug Application (NDA) holder of brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, which is sold under the COMBIGAN® trademark. The New Drug Application (NDA) for Combigan was approved by the US Food and Drug Administration (FDA) in October 2007. Allergan, Plc is a global specialty pharmaceutical company which develops, manufactures, markets and distributes branded pharmaceutical products, aesthetic products, biosimilar and over-the-counter pharmaceutical products. In 2015, Actavis, Plc acquired Allergan, Inc. for approximately $77 billion and subsequently changed its name to Allergan, Plc. In 2015, the global revenues for Alphagan and Combigan totaled $411.1 million ($285 million from the US market), which accounted for 2.7% of Allergans total net revenues.Allergan holds at least six active patents protecting Combigan from generic competition.